Genomic rearrangements are a hallmark of childhood solid tumors, but their mutational causes 46 remain poorly understood. Here, we identify the piggyBac transposable element derived 5 47 57 catalytic residues in the PGBD5 transposase domain, as well as end-joining DNA repair, and 58 induced distinct structural rearrangements, involving PSS-associated breakpoints, similar to 59 those found in primary human rhabdoid tumors. This defines PGBD5 as an oncogenic mutator 60 and provides a plausible mechanism for site-specific DNA rearrangements in childhood and 61 adult solid tumors. 62 63 64 65 66 67 68 131 individually-matched tumor versus normal paired blood specimens from children with extra-132 cranial rhabdoid tumors that are generally characterized by inactivating mutations of SMARCB1 133 10 . By virtue of their repetitive nature, sequences derived from transposons present challenges to 134 genome analysis. Thus, we reasoned that genome analysis approaches that do not rely on short-135 read alignment algorithms, such as the local assembly-based algorithm laSV and the tree-based 136
(PGBD5) gene as an enzymatically active human DNA transposase expressed in the majority of 48 rhabdoid tumors, a lethal childhood cancer. Using assembly-based whole-genome DNA 49 sequencing, we observed previously unknown somatic genomic rearrangements in primary 50 human rhabdoid tumors. These rearrangements were characterized by deletions and inversions 51 involving PGBD5-specific signal (PSS) sequences at their breakpoints, with some recurrently 52 targeting tumor suppressor genes, leading to their inactivation. PGBD5 was found to be 53 physically associated with human genomic PSS sequences that were also sufficient to mediate 54 PGBD5-induced DNA rearrangements in rhabdoid tumor cells. We found that ectopic expression 55 of PGBD5 in primary immortalized human cells was sufficient to promote penetrant cell 56 transformation in vitro and in immunodeficient mice in vivo. This activity required specific Introduction 69 Whole-genome analyses have now produced near-comprehensive topographies of coding 70 mutations for certain human cancers, enabling both detailed molecular studies of cancer 71 pathogenesis and potential of precisely targeted therapies 1-5 . For certain childhood cancers, 72 recent studies have begun to reveal the essential functions of complex non-coding structural 73 variants that can induce aberrant expression of cellular proto-oncogenes 6,7 . However, for many 74 aggressive childhood cancers including embryonal tumors, such studies have identified distinct 75 cancer subtypes that have no discernible coding mutations [8] [9] [10] [11] . In addition, while for some 76 cancers, defects in DNA damage repair have been suggested to explain their increased incidence 77 at a relatively young age, the causes of complex genomic rearrangements in cancers of young 78 children without apparent widespread genomic instability remain largely unknown. 79 Rhabdoid tumor is a prototypical example of this question. Rhabdoid tumors occur in the 80 developing tissues of infants and children, leading to tumors with neuroectodermal, epithelial 81 and mesenchymal components in the brain, liver, kidney and other organs 10, 12, 13 . Rhabdoid 82 tumors that cannot be cured with surgery are generally chemotherapy resistant and almost 83 uniformly lethal 14 . Rhabdoid tumors exhibit inactivating mutations of SMARCB1, generally as a 84 result of genomic rearrangements of the 22q11.2 chromosomal locus 15 . These mutations can be 85 inherited as part of the rhabdoid tumor predisposition syndrome, but are not thought to involve 86 chromosomal instability 13 . While SMARCB1 mutations are sufficient to cause rhabdoid tumors 87 in mice 16 , human rhabdoid tumors have been observed to have multiple molecular subtypes and 88 rearrangements of additional chromosomal loci that are poorly understood 9,10,17,18 . These 89 findings suggest that additional genetic elements and molecular mechanisms may contribute to 90 the pathogenesis of rhabdoid tumors. 91 In humans, nearly half of the genome is comprised by sequences derived from 92 transposons, including both autonomous and non-autonomous mobile genetic elements 19 . The 93 majority of human genes that encode enzymes that can mobilize transposons appear to be 94 catalytically inactive, with the exception of L1 long interspersed repeated sequences (LINEs) 95 that appear to induce structural genomic variation in human neurons and adenocarcinomas 20-22 , 96 Mariner transposase-derived SETMAR that functions in DNA repair 23 , and Transib-like DNA 97 transposase RAG1/2 that catalyzes somatic recombination of V(D)J receptor genes in 98 lymphocytes 24 . In particular, aberrant activity of RAG1/2 in lymphoblastic leukemias and 99 lymphomas can induce the formation of chromosomal translocations that generate transforming 100 fusion genes [25] [26] [27] . The identity of and mechanisms by which similar genomic rearrangements 101 may be formed in childhood solid tumors are unknown, but the existence of additional human 102 recombinases that can induce somatic DNA rearrangements has long been hypothesized 28 . 103 Recently, human PGBD5 and THAP9 have been found to catalyze transposition of 104 synthetic DNA transposons in human cells 29, 30 . The physiologic functions of these activities are 105 currently not known. PGBD5 is distinguished by its deep evolutionary conservation among 106 vertebrates (~500 million years) and developmentally restricted expression in tissues from which 107 childhood embryonal tumors, including rhabdoid tumors, are thought to originate 30, 31 . PGBD5 is 108 transcribed as a multi-intronic and non-chimeric transcript from a gene that encodes a full-length 109 transposase that became immobilized on human chromosome 1 30, 31 First, we analyzed the expression of PGBD5 in large, well-characterized cohorts of 123 primary childhood and adult tumors ( Supplementary Fig. 1a ). We observed that PGBD5 is 124 highly expressed a variety of childhood and adult solid tumors, including rhabdoid tumors, but 125 not in acute lymphoblastic or myeloid leukemias ( Supplementary Fig. 1a ). The expression of 126 PGBD5 in rhabdoid tumors was similar to that of embryonal tissues from which these tumors are 127 thought to originate, and was not significantly associated with currently defined molecular 128 subgroups or patient age at diagnosis ( Supplementary Fig. 1a Using this assembly-based approach, we observed recurrent rearrangements of the 139 SMARCB1 gene on chromosome 22q11 in nearly all cases examined, consistent with the 140 established pathogenic function of inactivating mutations of SMARCB1 in rhabdoid 141 tumorigenesis ( Fig. 1a ). In addition, we observed previously unrecognized somatic deletions, 142 inversions and translocations involving focal regions of chromosomes 1, 4, 5, 10, and 15 (median 143 = 3 per tumor), which were recurrently altered in more than 20% of cases ( Fig. 1a , Data S1). 144 These results indicate that in addition to the pathognomonic mutations of SMARCB1, human 145 rhabdoid tumors are characterized by additional distinct and recurrent genomic rearrangements. 146 To determine whether any of the observed genomic rearrangements may be related to 147 PGBD5 DNA transposase or recombinase activity, we first used a forward genetic screen to 148 identify PGBD5-specific signal (PSS) sequences that were specifically found at the breakpoints 149 of PGBD5-induced deletions, inversions and translocations that caused inactivation of the 150 HPRT1 gene in a thioguanine resistance assay 32 . Using these PSS sequences as templates for 151 supervised analysis of the somatic genomic rearrangements in primary human rhabdoid tumors, 152 we identified specific PSS sequences associated with the breakpoints of genomic rearrangements 153 in rhabdoid tumors (p = 1.1 x 10 -10 , hypergeometric test; Fig. 1b , Supplementary Fig. 2 ). By 154 contrast, we observed no enrichment of the RAG1/2 recombination signal (RSS) sequences at the 155 breakpoints of somatic rhabdoid tumor genomic rearrangements, in spite of their equal size to 156 PSS sequences, consistent with the lack of RAG1/2 expression in rhabdoid tumors. Likewise, we 157 did not find significant enrichment of PSS motifs at the breakpoints of structural variants and 158 genomic rearrangements in breast carcinomas that lack PGBD5 expression, even though these 159 breast carcinoma genomes were characterized by high rates of genomic instability (Data S1). In 160 total, 580 (52%) out of 1121 somatic genomic rearrangements detected in rhabdoid tumors 161 contained PSS sequences near the rearrangement breakpoints (Data S1). 162 Overall, the majority of the observed rearrangements were deletions and translocations 163 ( Fig. 1a, Supplementary Fig. 3a ). Notably, we found recurrent PSS-containing genomic 164 rearrangements affecting the CNTNAP2, TENM2, TENM3, and TET2 genes ( Fig. 1a -c, 165 Supplementary Fig. 3c , Data S1). Using allele-specific polymerase chain reaction (PCR) 166 followed by Sanger DNA sequencing, we confirmed three of the observed PGBD5-induced 167 intragenic CNTNAP2 deletions and rearrangement breakpoints ( Fig. 1c ). Likewise, we confirmed 168 somatic nature of mutations of CNTNAP2 and TENM3 by allele-specific PCR in matched tumor 169 and normal primary patient specimens ( Supplementary Fig. 3d -h).
170
CNTNAP2, a member of the neurexin family of signaling and adhesion molecules, has 171 been previously found to function as a tumor suppressor gene in gliomas 35 . Consistent with the 172 potential pathogenic functions of the apparent PGBD5-induced CNTNAP2 rearrangements in 173 rhabdoid tumors found in our analysis, CNTNAP2 has also been recently reported to be 174 recurrently deleted in an independent cohort of rhabdoid tumor patients 18 . By using comparative 175 RNA sequencing gene expression analysis, we found that recurrent genomic rearrangements of 176 CNTNAP2 in our cohort were indeed associated with significant reduction of its mRNA 177 transcript expression in genomically rearranged primary cases as compared to those lacking 178 CNTNAP2 rearrangements (p = 0.017, t-test; Fig. 1d ). Additional mechanisms, including as of 179 yet undetected mutations or silencing 35 , may contribute to the loss of CNTNAP2 expression in 180 apparently non-rearranged cases (Fig. 1d ). 181 Interestingly, some of the observed genomic rearrangements with PSS-containing 182 breakpoints in rhabdoid tumors involved SMARCB1 deletions ( Fig. 1a -b, Data S1), suggesting 183 that in a subset of rhabdoid tumors, PGBD5 activity may contribute to the somatic inactivation of 184 SMARCB1 in rhabdoid tumorigenesis. Similarly, we observed recurrent interchromosomal 185 translocations and complex structural variants containing breakpoints with the PSS motifs that 186 involved SMARCB1 (Fig. 1b , Data S1), including chromosomal translocations, previously 187 observed using cytogenetic methods 17 . For example, we verified the t(5;22) translocation using 188 allele-specific PCR followed by Sanger sequencing of the translocation breakpoint (Suppl. Fig.   189 3i-j). In all, these results indicate that human rhabdoid tumors exhibit recurrent complex genomic 190 rearrangements that are defined by PSS breakpoint sequences specifically associated with 191 PGBD5, at least some of which appear to be pathogenic and may be coupled with inactivating 192 mutations of SMARCB1 itself. 193 194 PGBD5 is physically associated with human genomic PSS sequences that are sufficient to 195 mediate DNA rearrangements in rhabdoid tumor cells 196 197 In prior studies, human PGBD5 has been found to localize to the cell nucleus 31 . To test 198 whether PGBD5 in rhabdoid tumor cells is physically associated with genomic PSS-containing 199 sequences, as would be predicted for a DNA transposase that induces genomic rearrangements, 200 we used chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) to determine 201 the genomic localization of endogenous PGBD5 in human G401 rhabdoid tumor cells. We 202 observed that human DNA regions bound by PGBD5 were significantly enriched for PSS motifs 203 (p = 2.9 x 10 -29 , hypergeometric test), in contrast to the scrambled PSS sequences of identical 204 composition, or the functionally unrelated RSS sequences of equal size that showed no 205 significant enrichment (p = 0.28 and 1.0, respectively, hypergeometric test; Fig. 2a ). 206 To test the hypothesis that PGBD5 can act directly on human PSS-containing DNA 207 sequences to mediate their genomic rearrangements, we used the previously established DNA Tables 5 & 6 ). This activity was specifically observed for transposon reporters with intact 231 transposons, but not those in which the essential 5'-GGGTTAACCC-3' hairpin structure was 232 mutated to 5'-ATATTAACCC-3' ( Supplementary Table 5) Supplementary Fig. 7a ). These results indicate that the PGBD5 transposase can specifically 269 transform human cells in the absence of chromosomal instability both in vitro and in vivo. transforming activity as wild-type GFP-PGBD5 ( Fig. 4b and 4d ). Importantly, we confirmed that 290 the catalytic mutants of GFP-PGBD5 on average retained their chromatin localization as 291 compared to wild-type PGBD5, as assessed using ChIP-seq ( Fig. 4c ). Although the D386A 292 mutant exhibited reduced transposition activity in reporter assays in vitro 30 , its expression 293 induced wild-type transforming activity in vivo (Fig. 4d ). This suggests that the transforming Supplementary Fig. 7b ). 306 When transplanted into immunodeficient mice whose doxycycline chow treatment (-Dox) was 307 stopped upon macroscopic signs of tumor formation ( Fig. 5a , Supplementary Fig. 7c ), the 308 transduced cells retained essentially the same tumorigenicity as seen in continuously treated 309 (+Dox) animals or in those transplanted with constitutively expressing GFP-PGBD5 cells 310 ( Supplementary Fig. 7c ). Importantly, we confirmed the absence of measureable PGBD5 311 expression in tumors harvested from -Dox animals by Western immunoblotting (Fig. 5a , inset). isogenic RPE cells that are wild-type or deficient for the NHEJ cofactor PAXX, which stabilizes 334 the NHEJ repair complex and is required for efficient DNA repair 41 . In contrast to defects in 335 other NHEJ components, such as LIG4, PAXX deficiency does not appreciably alter cell growth 336 or viability but significantly reduces NHEJ efficiency without needing TP53 inactivation to 337 survive 41 . Thus, we generated RPE cells expressing doxycycline-inducible PGBD5 that were 338 PAXX +/+ or PAXX -/-, and confirmed the induction of PGBD5 and lack of PAXX expression by 339 Western immunoblotting (Fig. 6a ). Doxycycline-induced expression of PGBD5 in PAXX -/but 340 not isogenic PAXX +/+ RPE cells caused the accumulation of DNA damage-associated γH2AX 341 ( Fig. 6b, Supplementary Figure 8b) , apoptosis-associated cleavage of caspase 3 (Fig. 6c , 342 Supplementary Figure 8a) , and cell death ( Supplementary Figure 8c) . We confirmed the 343 requirement of NHEJ for the repair of PGBD5-induced rearrangements using Ku80-deficient 344 mouse embryonal fibroblasts (data not shown). Importantly, PGBD5-mediated induction of DNA 345 damage and cell death in NHEJ-deficient PAXX -/cells as compared to the isogenic NHEJ-346 proficient PAXX +/+ cells was nearly completely rescued by the mutation of 347 D168A/D194A/D386A residues, which are required for transposase activity of PGBD5 (Fig. 6d ). 348 Thus, NHEJ DNA repair is required for the survival of cells expressing active PGBD5. for over 90% of the genome (Data S1). As for the rhabdoid tumor genome analysis, we used the 360 assembly-based algorithm laSV as well as conventional techniques ( Supplementary Table 3 , 361 Supplementary Figs. 9-11, Data S1) 33,34 . This analysis led to the identification of distinct 362 genomic rearrangements, specifically in PGBD5-induced tumor cell genomes as compared to 363 control GFP and non-transduced RPE cells (Fig. 7a ). The identified rearrangements were 364 characterized by intra-chromosomal deletions with a median length of 183 bp, consistent with 365 their apparent limited detectability by conventional genome analysis methods, as well as 366 inversions, duplications and translocations ( Supplementary Fig. 12a -c, Data S1). As with 367 genomic rearrangements found in primary human tumors (Fig. 1) , the analysis of genomic 368 rearrangements found in PGBD5-transformed RPE cells detected significant enrichment of PSS 369 motifs at the breakpoints of PGBD5-induced tumor structural variants (p = 7.2 x 10 -3 , 370 hypergeometric test; Fig. 7b , Data S1). By contrast, breakpoints of structural variants in GFP 371 control RPE cell genomes, presumably at least in part due to normal genetic variation, exhibited 372 no enrichment for PSS motifs (p = 0.37). We independently verified these findings using the 373 direct tree graph-based read comparative SMuFin analysis method ( Supplementary Fig. 12a , 374 Data S1). In addition, we assessed five of these rearrangements using variant and wild-type 375 allele-specific PCR followed by Sanger DNA sequencing of rearrangement breakpoints to 376 confirm that they are specifically present in PGBD5-transformed but not control GFP-transduced 377 RPE cells ( Supplementary Fig. 12d-h) . Additionally, we did not find genomic rearrangement 378 breakpoints containing RSS sequences that are targeted by the RAG1/2 recombinase which is not 379 expressed in RPE cells. We also did not find evidence of structural alterations of the annotated 380 human MER75 and MER85 piggyBac-like transposable elements, in agreement with the distinct 381 evolutionary history of human PGBD5 30 . Notably, we found that the genomic rearrangements 382 and structural variants observed in PGBD5-induced RPE tumors were significantly enriched for 383 regulatory DNA elements important for normal human embryonal as opposed to adult tissue 384 development ( Fig. 7c , Supplementary Table 4 ). 385 To identify genomic rearrangements that may be functionally responsible for PGBD5- 386 induced cell transformation, we analyzed the recurrence of PGBD5-induced genomic 387 rearrangements in 10 different RPE tumors from independent transduction experiments in 388 individual mouse xenografts. We detected 59 PGBD5-induced structural variants per tumor, 42 389 (71%) of which were deletions, 36 (61%) affected regulatory intergenic elements, with 13 (22%) 390 containing PSS motifs at their breakpoints (Data S1). In particular, we identified recurrent and 391 clonal PSS-associated rearrangements of WWOX, including duplication of exons 6-8 ( Fig. 7d) . 392 WWOX is a tumor suppressor gene that controls TP53 signaling 42 . We confirmed the duplication 393 of exons 6-8 of WWOX by PCR and Sanger DNA sequencing (Fig. 7d) , and tested its functional 394 consequence on WWOX protein expression by Western immunoblotting (Fig. 7e ). Remarkably, Supplementary Fig. 13a & d) . Consistent with the tumorigenic function of PGBD5-induced 403 mutations of WWOX, we found that WWOX inactivation was necessary but not sufficient to 404 maintain clonogenicity of PGBD5-transformed RPE tumor cells in vitro ( Supplementary Fig.   405 13b-c & e-f). Thus, PGBD5-induced cell transformation involves site-specific genomic 406 rearrangements that are associated with PGBD5-specific signal sequence breakpoints that 407 recurrently target regulatory elements and tumor suppressor genes (Fig. 7f ). We have now found that primary human rhabdoid tumor genomes exhibit signs of 414 PGBD5-mediated DNA recombination, involving recurrent mutations of previously elusive 415 rhabdoid tumor suppressor genes (Fig. 1) . These genomic rearrangements involve breakpoints Supplementary Fig. 14) . We confirmed that the catalytic aspartic acid mutants of PGBD5 on 430 average maintain chromatin localization of wild-type PGBD5. It is also possible that these 431 residues contribute to cell transformation due to their interaction with cellular cofactors or 432 assembly of DNA regulatory complexes, or still yet unknown nuclease-independent functions 433 that contribute to cell transformation. Notably, the recurrence patterns of PGBD5-induced genomic rearrangements in rhabdoid tumors 453 indicate that even for rare cancers, more comprehensive tumor genome analyses will be 454 necessary to define the spectrum of causal genomic lesions and potential therapeutic targets. 455 Similarly, given the existence of distinct molecular subtypes of rhabdoid tumors 9,10 , it will be Detailed Materials and Methods, Supplementary Figures 1-14 , Supplementary Tables 1-478 7, and Supplementary Data S1. Genome and chromatin immunoprecipitation sequencing data 479 have been deposited to the NCBI Sequence Read Archive and Gene Expression Omnibus as marked for PSS-containing breakpoints (outer ring, arrowheads), recurrence (middle ring histogram, rearrangements occurring in ≥3 out of 31 samples and highlighted in red for rearrangements with recurrence frequency greater than 13%), and structural variant type (inner lines, as color-labeled). Recurrently rearranged genes are labeled. (b) Representation of 21 structural variant breakpoints in rhabdoid tumors identified to harbor PSS sequences (red) within 10 bp of the breakpoint junction (arrowhead). (c) Recurrent structural variants of CNTNAP2 (red) with gene structure (black) and Sanger sequencing of the rearrangement breakpoints. (d) CNTNAP2 mRNA expression in primary rhabdoid tumors as measured using RNA sequencing in CNTNAP2 mutant (red) as compared to CNTNAP2 intact (blue) specimens (* p = 0.017 by t-test for intact vs. mutant CNTNAP2).
Fig. 4. PGBD5 transposase activity is necessary to transform human cells. (a)
Western blot of GFP in RPE cells expressing GFP-PGBD5, GFP-PGBD5 mutants, and GFP compared to RPE cells (DM = double mutant D194A/D386A; TM = triple mutant D168A/D194A/D386A). (b) Number of refractile foci formed in monolayer culture in RPE and BJ cells stably expressing GFP-PGBD5 or control GFP, as compared to non-transduced cells and cells expressing GFP-PGBD5 mutants (red = transposase deficient mutants, blue = transposase proficient mutants, * p = 2.1 x 10 -4 for D168A vs. GFP-PGBD5, p = 2.7 x 10 -6 for D194A vs. GFP-PGBD5, p = 1.8 x 10 -6 for D194A/D386A vs. GFP-PGBD5, p = 2.4 x 10 -7 for D168A/D194A/D386A vs. GFP-PGBD5). Error bars represent standard deviations of three biological replicates. (c) Composite plot of ChIP-seq of GFP-PGBD5 (green), as compared to the GFP-PGBD5 D168A/D194A/D386A catalytic TM mutant (orange) and GFP control (purple). (d) Kaplan-Meier analysis of tumor-free survival of mice with subcutaneous xenografts of RPE cells expressing GFP-PGBD5 as compared to cells expressing GFP-PGBD5 mutants (n = 10 per group, p < 0.0001 by log-rank test).
Fig. 5. Transient PGBD5 transposase expression is sufficient to transform human cells. (a)
Tumor volume of RPE cells as a function of time in primary (light gray box) and secondary (dark gray box) transplants, with PGBD5 expression induced using doxycycline (black), as indicated. RPE cells were treated with doxycycline in vitro for 10 days prior to transplantation. Arrowhead denotes withdrawal of doxycycline from the diet (red). Inset: Western blot of PGBD5 protein, as compared to actin control in cells derived from tumors after primary transplant. 
